The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
A Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients
Open accessAbstract
BACKGROUND: Dengue is the most common arboviral infection of humans. There are currently no specific treatments for dengue. Balapiravir is a prodrug of a nucleoside analogue (called R1479) and an inhibitor of hepatitis C virus replication in vivo. METHODS: We conducted in vitro experiments to determine the potency of balapiravir against dengue viruses and then an exploratory, dose-escalating, randomized placebo-controlled trial in adult male patients with dengue with <48 hours of fever. RESULTS: The clinical and laboratory adverse event profile in patients receiving balapiravir at doses of 1500 mg (n = 10) or 3000 mg (n = 22) orally for 5 days was similar to that of patients receiving placebo (n = 32), indicating balapiravir was well tolerated. However, twice daily assessment of viremia and daily assessment of NS1 antigenemia indicated balapiravir did not measurably alter the kinetics of these virological markers, nor did it reduce the fever clearance time. The kinetics of plasma cytokine concentrations and the whole blood transcriptional profile were also not attenuated by balapiravir treatment. CONCLUSIONS: Although this trial, the first of its kind in dengue, does not support balapiravir as a candidate drug, it does establish a framework for antiviral treatment trials in dengue and provides the field with a clinically evaluated benchmark molecule. CLINICAL TRIALS REGISTRATION: NCT01096576.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dengue Viremia Titer, Antibody Response Pattern, and Virus Serotype Correlate with Disease Severity
Vaughn, D. W., Green, S., Kalayanarooj, S., Innis, B. L., Nimmannitya, S., Suntayakorn, S., Endy, T. P., Raengsakulrach, B., Rothman, A. L., Ennis, F. A., et al. (2000) · The Journal of Infectious Diseases · doi:10.1086/315215 · Cited by 1,632
Libraty, D. H., Young, P. R., Pickering, D., Endy, T. P., Kalayanarooj, S., Green, S., Vaughn, D. W., Nisalak, A., Ennis, F. A., & Rothman, A. L. (2002) · The Journal of Infectious Diseases · doi:10.1086/343813 · Cited by 739
Libraty, D. H., Endy, T. P., Houng, H. H., Green, S., Kalayanarooj, S., Suntayakorn, S., Chansiriwongs, W., Vaughn, D. W., Nisalak, A., Ennis, F. A., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/340365 · Cited by 494
Yap, T. L., Xu, T., Chen, Y.-L., Malet, H., Egloff, M.-P., Canard, B., Vasudevan, S. G., & Lescar, J. (2007) · Journal of Virology · doi:10.1128/jvi.02283-06 · Cited by 445
An adenosine nucleoside inhibitor of dengue virus
Yin, Z., Chen, Y.-L., Schul, W., Wang, Q.-Y., Gu, F., Duraiswamy, J., Kondreddi, R. R., Niyomrattanakit, P., Lakshminarayana, S. B., Goh, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907010106 · Cited by 390
Cost of Dengue Cases in Eight Countries in the Americas and Asia: A Prospective Study
Suaya, J. A., Shepard, D. S., Siqueira, J. B., Martelli, C. T., Lum, L. C. S., Tan, L. H., Kongsin, S., Jiamton, S., Garrido, F., Montoya, R., et al. (2009) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2009.80.846 · Cited by 379
A Randomized Controlled Trial of Chloroquine for the Treatment of Dengue in Vietnamese Adults
Tricou, V., Minh, N. N., Van, T. P., Lee, S. J., Farrar, J., Wills, B., Tran, H. T., & Simmons, C. P. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000785 · Cited by 329
Self-citationWhitehorn, J., & Simmons, C. P. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.022 · Cited by 282
Self-citationStrategies for development of dengue virus inhibitors
Noble, C. G., Chen, Y.-L., Dong, H., Gu, F., Lim, S. P., Schul, W., Wang, Q.-Y., & Shi, P.-Y. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.12.011 · Cited by 276
Anders, K. L., Nguyet, N. M., Van Vinh Chau, N., Hung, N. T., Thuy, T. T., Lien, L. B., Farrar, J., Wills, B., Hien, T. T., & Simmons, C. P. (2011) · The American Society of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2011.10-0476 · Cited by 253
Self-citationHoang, L. T., Lynn, D. J., Henn, M., Birren, B. W., Lennon, N. J., Le, P. T., Duong, K. T. H., Nguyen, T. T. H., Mai, L. N., Farrar, J. J., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01224-10 · Cited by 137
Self-citationHue, K. D. T., Tuan, T. V., Thi, H. T. N., Bich, C. T. N., Anh, H. H. L., Wills, B. A., & Simmons, C. P. (2011) · Journal of Virological Methods · doi:10.1016/j.jviromet.2011.08.002 · Cited by 115
Self-citation
Cited by
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Wilm, A., Aw, P. P. K., Bertrand, D., Yeo, G. H. T., Ong, S. H., Wong, C. H., Khor, C. C., Petric, R., Hibberd, M. L., & Nagarajan, N. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks918 · Cited by 1,372
Self-citationGuzman, M. G., & Harris, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60572-9 · Cited by 1,345
Guzman, M. G., Gubler, D. J., Izquierdo, A., Martinez, E., & Halstead, S. B. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.55 · Cited by 762
Wilder-Smith, A., Ooi, E.-E., Horstick, O., & Wills, B. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32560-1 · Cited by 692
Metadata
- Authors
- Nguyen, N. M., Tran, C. N. B., Phung, L. K., Duong, K. T. H., Huynh, H. L. A., Farrar, J., Nguyen, Q. T. H., Tran, H. T., Nguyen, C. V. V., Merson, L., Hoang, L. T., Hibberd, M. L., Aw, P. P. K., Wilm, A., Nagarajan, N., Nguyen, D. T., Pham, M. P., Nguyen, T. T., Javanbakht, H., Klumpp, K., Hammond, J., Petric, R., Wolbers, M., Nguyen, C. T., & Simmons, C. P.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-17
- Volume
- 207
- Issue
- 9
- Pages
- 1442-1450
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2103800735
- Cited by
- 293
- References
- 12
- FWCI
- 15.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.